The company has substantially boosted its course of an new treatment for ATTR-CM, leveraging the compound. Early patient results indicates potential benefits for individuals affected by the debilitating illness. This https://biotech956594.onzeblog.com/42310506/bridgebio-advances-amyloidosis-management-through-the-therapy